Cardiovascular disease and the kidney

References

• Jones CA, McQuillan GM, Kusek J W, et al. Serum Creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32(6): 992–9
   PubMed Web of Science ®Google Scholar
• Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56(6): 2214–9
   PubMed Web of Science ®Google Scholar
• Jungers P, Khoa TN, Massy ZA, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France district. Nephrol Dial Transplant 1999; 14(4): 898–902
   PubMed Web of Science ®Google Scholar
• Chertow GM, Normand SL, Silva LR, et al. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the Cooperative Cardiovascular Project. Am J Kidney Dis 2000; 35(6): 1044–51
   PubMed Web of Science ®Google Scholar
• Patient mortality and survival. United States Renal Data System. Am J Kidney Dis 1998; 32(2 Suppl 1): S69–80
   Google Scholar
• Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiography disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47(1): 186–92
   PubMed Web of Science ®Google Scholar
• Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34(l):125–34
   PubMedGoogle Scholar
• Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7(1): 158–65
   PubMedGoogle Scholar
• Rigatto C, Foley RN, Kent GM, et al. Long- term changes in left ventricular hypertrophy after renal transplantation. Transplantation 2000; 70(4): 570–5
   PubMedGoogle Scholar
• Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001; 37(6): 1191–200
   PubMedGoogle Scholar
• Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28(1): 53–61
   PubMed Web of Science ®Google Scholar
• Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000; 15(5): 650–8
   PubMedGoogle Scholar
• Obrador GT, Ruthazer R, Arora P, et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999; 10(8): 1793–800
   PubMedGoogle Scholar
• Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35(7): 1737–44
   PubMed Web of Science ®Google Scholar
• Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35(6): 1226–37
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342(20): 1478–83
   PubMed Web of Science ®Google Scholar
• Tonelli M, Bohm C, Pandeya S, et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001; 37(3): 484–9
   PubMed Web of Science ®Google Scholar
• Levin A, Djurdjev O, Barrett B, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 2001; 38(6): 1398–407
   PubMedGoogle Scholar
• McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal dysfunction in the coronary care unit. J Am Coll Cardiol 2000; 36(3): 679–84
   PubMedGoogle Scholar
• McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103(5): 368–75
   PubMed Web of Science ®Google Scholar
• Lowe LP, Greenland P, Ruth KJ, et al. Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158(18): 2007–14
   PubMedGoogle Scholar
• Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100(13): 1481–92
   PubMed Web of Science ®Google Scholar
• Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160(8): 1093–100
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Committees Working Group. Am J Kidney Dis 2000; 36(3): 646–61
   PubMed Web of Science ®Google Scholar
• Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a metaanalysis of randomized trials. Angiotensin- Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127(5): 337–45
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000; 160(5): 685–93
   PubMed Web of Science ®Google Scholar
• Bakris G, White D. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens 1997; 11(1): 35–8
   PubMedGoogle Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–86
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulpho-nylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53
   PubMed Web of Science ®Google Scholar
• Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58(1): 293–301
   PubMed Web of Science ®Google Scholar
• Levin A, Duncan L, Djurdjev O, et al. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Nephrol 2000; 53(2): 140–6
   PubMedGoogle Scholar